U.S Physical Therapy Research and Development Expenses 2012-2026 | USPH
U.S Physical Therapy research and development expenses from 2012 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
|
U.S Physical Therapy Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
| 2013 | |
| 2012 | |
| 2011 | |
|
U.S Physical Therapy Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | |
| 2025-06-30 | |
| 2025-03-31 | |
| 2024-12-31 | |
| 2024-09-30 | |
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | |
| 2018-09-30 | |
| 2018-06-30 | |
| 2018-03-31 | |
| 2017-12-31 | |
| 2017-09-30 | |
| 2017-06-30 | |
| 2017-03-31 | |
| 2016-12-31 | |
| 2016-09-30 | |
| 2016-06-30 | |
| 2016-03-31 | |
| 2015-12-31 | |
| 2015-09-30 | |
| 2015-06-30 | |
| 2015-03-31 | |
| 2014-12-31 | |
| 2014-09-30 | |
| 2014-06-30 | |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $0.951B | $0.781B |
| U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh's clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company's growth, are structured like the de novo partnerships, with significant ownership retained by founders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $25.458B | 11.41 |
| Quest Diagnostics (DGX) | United States | $21.429B | 19.09 |
| DaVita (DVA) | United States | $13.461B | 17.88 |
| Elanco Animal Health (ELAN) | United States | $11.937B | 24.39 |
| Encompass Health (EHC) | United States | $9.789B | 17.34 |
| Chemed (CHE) | United States | $5.788B | 22.15 |
| RadNet (RDNT) | United States | $4.385B | 121.22 |
| LifeStance Health (LFST) | United States | $3.570B | 153.42 |
| Option Care Health (OPCH) | United States | $3.345B | 13.83 |
| Astrana Health (ASTH) | United States | $2.206B | 26.75 |
| Addus HomeCare (ADUS) | United States | $1.774B | 16.76 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.725B | 12.98 |
| Pennant (PNTG) | United States | $1.169B | 32.65 |
| Daxor (DXR) | United States | $0.055B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.031B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |